Evidence map›Paper›PMID 39119327›Full record

ArticleIndian journal of dermatology

Management of Pustular Psoriasis; The Way Ahead.

Shrichand G Parasramani, Bikash R Kar, Sushil Tahiliani, Anchala Parthasarathi, Shekhar Neema, Satyaki Ganguly, Dharshini Sathishkumar, K Venkatachalam, Haritha Komeravelli, Jayakar Thomas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shrichand G ParasramaniFrom the Department of DVL, Lilavati Hospital, Mumbai, Maharashtra, India.
Bikash R KarDepartment of DVL, IMS and SUM Hospital, Bhubaneswar, Odisha, India.
Sushil TahilianiDepartment of DVL, P D Hinduja Hospital and Research Centre, Mumbai, Maharashtra, India.
Anchala ParthasarathiDirector, Anchala Skin Institute and Research Centre, Hyderabad, Telangana, India.
Shekhar NeemaDepartment of DVL, AFMC, Pune, Maharashtra, India.
Satyaki GangulyDepartment of DVL, AIIMS, Raipur, Chhattisgarh, India.
Dharshini SathishkumarDepartment of DVL, CMC, Vellore, Tamil Nadu, India.
K VenkatachalamDepartment of DVL, RIMS, Srikakulam, Andhra Pradesh, India.
Haritha KomeravelliConsultant Dermatologist, Hyderabad, Telangana, India.
Jayakar ThomasSenior Consultant Dermatologist, Apollo Hospitals and KK Child Trust Hospital, Chennai, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pustular psoriasis is a specialized variant of psoriasis which can be life threatening if not treated at the earliest. The pathogenesis has been recently linked to the role of interleukin 36. Apart from the corticosteroids, systemic antipsoriatics like acitretin, cyclosporine and methotrexate have been used with some success though unpredictable. With recent identification of role of IL-36 in the pathogenesis of pustular psoriasis, biologics targeting the IL-36 receptors have been used to manage the situation with high degree of success. This narrative review deals with the recent concepts of pathogenesis of pustular psoriasis as well as the current management scenario.

Indexed as

IL 36R inhibitorspustular psoriasissystemic treatmenttreatment

Identifiers

PMID39119327
PMCPMC11305487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.